Start of new generation of NSAIDs?
|
|
- Gary Norris
- 5 years ago
- Views:
Transcription
1 Vet Times The website for the veterinary profession Start of new generation of NSAIDs? Author : Peter Lees Categories : Vets Date : May 16, 2011 Peter Lees discusses development of robenacoxib, an NSAID with high COX-2 selectivity NSAIDS are the single most commonly prescribed drugs in small animal medicine, yet a significant percentage of the side effects and adverse events recorded annually by the VMD can be directly attributed to their use. This article will discuss the properties of NSAIDs as they have evolved for the veterinary market, specifically robenacoxib, a new entrant into the market in 2009 (King et al, 2009; Giraudel et al, 2009; Jung et al, 2009; Schmid et al, 2010), which is the active ingredient in Onsior, marketed by Novartis. NSAID development: COX-1: COX-2 ratios The discovery in 1991 that there are two isoforms of COX, now designated as COX-1 and COX-2 (Xie et al, 1991), was heralded as a major pharmacological advance, with positive therapeutic benefit in relation to NSAID safety. COX-1 was recognised as a constitutive enzyme, present at basal levels in most body cell types. Its roles include platelet aggregation in blood clotting, gastroprotection and, at least partially, renoprotection. The potential side effects of COX-1 inhibition, therefore, include failure to control haemorrhage, perforation, ulceration and bleeding of the gastrointestinal tract, and acute renotoxicity. COX-2 was initially classified as an inducible isoform, synthesised in response to tissue damage 1 / 5
2 both at the site of damage and in the central nervous system. Development of selective COX-2 inhibitors was logical, on the grounds they would retain (but not necessarily improve) therapeutic effects of non-selective inhibitors and decrease classic side effects of non-selective NSAIDs ( Figure 1 ). A potency ratio of 30: 1 or greater will normally ensure that COX-1 inhibition is slight to moderate and of short duration with clinically recommended doses. However, it is now recognised that COX-2 is also a constitutive enzyme in kidneys, eyes, central nervous system and vascular wall. Consequently, there is a concern that, for example, renotoxicity of all NSAIDs, including the coxibs, may be partly due to COX-2 inhibition. It has also been shown experimentally that COX-2 generates not only pro-inflammatory mediators, such as prostaglandin E2 (PGE2), in the early stages of acute inflammation, but also anti-inflammatory prostaglandins in the later stage of tissue repair. The introduction of preferential or selective COX-2 inhibitors into canine medicine has largely achieved the objectives of retained efficacy and some aspects of reduced toxicity. However, the question is whether other properties exist that, in addition to the COX-2 selectivity of coxibs, may improve the safety profile. Pharmacokinetics of NSAIDS When NSAIDs are administered orally or parenterally, the circulatory system delivers the drug to the biophase, that is, the site of action. A successful clinical response is achieved if effective concentrations are attained for most of the inter-dose interval. The concern, however, is that many NSAIDs, both nonselective and COX-2 selective, are delivered to all organs and tissues, not just those targeted for therapy, and this can lead to continuous exposure of noninflamed organs and tissues. NSAID accumulation at peripheral sites of tissue damage The propensity to accumulate preferentially at sites of tissue damage has been demonstrated by some NSAIDs that are nonselective in their COX inhibitory actions, and for one of the newer coxibs, robenacoxib, licensed for use in canine and feline medicine. NSAIDs accumulating in inflamed tissue have in common the properties outlined by Lees et al (2004); Brune and Furst (2007; see Table 1 ). These are compatible with retention of efficacy and the potential for an improved safety profile of tissuetargeting NSAIDs. A high degree (greater than 98 per cent) of binding to plasma protein. A high degree of binding to plasma protein generally limits the extravascular distribution of some, but not all, NSAIDs to most tissues; volumes of distribution are small. However, when tissues are 2 / 5
3 damaged, the permeability of capillaries is markedly increased and plasma containing protein (with attached NSAID) leaks into the interstitial space to cause the characteristic pitting oedema of acute inflammation. Short half-life. A relatively rapid decrease in plasma concentration (as indicated by terminal half-life or mean residence time in the body) reduces the duration of exposure of the body s well-perfused organs (heart, liver and kidney) to high concentrations of the drug within the inter-dose interval. A carboxylic or enolic acid grouping in the molecule. NSAIDs carrying either an enolic or carboxylic acid group are mildly acidic, as are the exudates at the sites of inflammation (Guthrie et al, 1994; Brune and Furst, 2007). Other coxibs in veterinary use are not weak acids. Significantly higher total concentrations in exudate than in transudate and slow rate of elimination from inflammatory exudate. Through the above mechanisms, Lees at al (2004) and Brune and Furst (2007) predicted the achievement of persistent concentrations in inflammatory exudate for weak acid NSAIDs with short plasma halflives, which was confirmed by experimental data. Tissue selectivity of robenacoxib As shown in Table 1, robenacoxib possesses all the above properties required for tissue selectivity (accumulation at a site of inflammation). This quality has been proven in feline studies by Pelligand et al (2011; see Figure 2 ). The slow clearance from exudate explains its long duration of action in inhibiting the synthesis of PGE2, a key mediator of pain in osteoarthritis (OA; King et al 2009; Pelligand et al, 2011). A further study, by Silber et al (2010), compared the penetration of robenacoxib into inflamed versus non-inflamed stifle joints in beagles. The residence time of robenacoxib was similar in both blood and normal joints, but greater in the inflamed stifle. At 10 hours, concentrations in synovial fluid were approximately three-fold higher in the inflamed stifle than in the blood and normal joint. The study also concluded that the rate of entry of robenacoxib into canine synovial fluid was 1.8 times faster in clinical subjects with osteoarthritic joints compared to healthy joints. A final consideration in relation to tissue selectivity is the time course of binding and de-binding of robenacoxib to COX isoforms. Robenacoxib de-binding is virtually instantaneous from COX-1, whereas it forms a slowly reversible complex with COX-2; the half-life for dissociation from COX-2 is approximately 25 minutes (King et al, 2009). 3 / 5
4 Implications of tissue selectivity Rapid clearance from blood considerably reduces the duration of exposure of the pharmacokinetic central compartment, which includes the well-perfused organs (kidney, liver, heart and blood vessels), to high robenacoxib concentrations. At the same time, robenacoxib is cleared much more slowly from sites of inflammation and synovial fluid in dogs with OA. These observations, together with high selectivity for COX-2, account for the safety profile of robenacoxib in dogs and cats. References Brune K and Furst D E (2007). Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability?, Rheumatology 46: Giraudel J M, Toutain P L, King J N and Lees P (2009). Differential inhibition of cyclooxygenase isoenzymes in the cat by the NSAID robenacoxib, Journal of Veterinary Pharmacology and Therapeutics 32: Guthrie A J, Short C R, Swan G E, Mulders M S G, Killeen V M and Nurton J P (1994). Proceedings of the 6th International Congress of the European Association for Veterinary Pharmacology and Toxicology, Blackwell Scientific Publications, Oxford, UK: Jung M, Lees P, Seewald W and King J N (2009). Analytical determination and pharmacokinetics of robenacoxib in the dog, Journal of Veterinary Pharmacology and Therapeutics 32: King J N, Dawson J, Esser R E, Fujimoto R, Kimble E F, Maniara W, Marshall, P J, O Byrne L, Quadros E, Toutain P L and Lees P (2009). Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2, Journal of Veterinary Pharmacology and Therapeutics, 32: King J N, Rudaz C, Borer L, Jung M, Seewald W and Lees P (2010). In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study, Research in Veterinary Science 88: Lees P, Landoni M F, Giraudel J and Toutain P L (2004). Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest, Journal of Veterinary Pharmacology and Therapeutics 27: Pelligand L, King J N, Toutain P L, Elliott J and Lees P (2011). PK-PD modelling of robenacoxib in a feline tissue cage model of inflammation, Journal of Veterinary Pharmacology and Therapeuticsin press. Schmid V B, Seewald W, Lees P and King J N (2010). In vitro and ex vivo inhibition of COX isoforms by robenacoxib in the cat: a comparative study, Journal of Veterinary Pharmacology and Therapeutics 33: Silber H E, Burgener C, Letellier M, Peyrou M, Jung M, King J N, Gruet P and Giraudel J M (2010). Population pharmacokinetic analysis of blood and joint synovial fluid concentrations of robenacoxib from healthy dogs and dogs with osteoarthritis, Pharmaceutical Research 27: 2,633-2,645. Xie W L, Chipman J G, Robertson D S, Erikson R L and Simmons D L (1991). Expression of a mitogenresponsive gene encoding prostaglandin synthase is regulated by mrna 4 / 5
5 Powered by TCPDF ( splicing, Proceedings of the National Academy of Sciences of the United States of America 88: 2,692-2, / 5
Just where it s needed.
Relief. Just where it s needed. Tissue-selective 7,8 Strong safety profile 5,6,10,11 For dogs and cats Onsior is available in a range of convenient and easy-to-dose formulations. Injectable solution for
More informationMeloxicam vs etodolac cox 2 inhibition
Meloxicam vs etodolac cox 2 inhibition The Borg System is 100 % Meloxicam vs etodolac cox 2 inhibition of GI. Aspirin inhibits plt aggregration via inhibition of platelet COX. Meloxicam least. Etodolac
More informationNon-steroidal anti-inflammatory drugs (NSAIDs) are used widely to relieve pain, with or without
May 2013 Contents About NSAIDs What about COXselectivity? How effective are NSAIDs? Adverse effects of NSAIDs How frequent are the adverse effects of NSAIDs? General prescribing guidelines for NSAIDs What
More informationMetacam 1.5 mg/ml oral suspension for dogs
Metacam 1.5 mg/ml oral suspension for dogs Species:Dogs Therapeutic indication:pharmaceuticals: Neurological preparations: Analgesics, Other NSAIDs, Locomotor (including navicular and osteoarthritis) Active
More informationNSAID Toxicity in Dogs & Cats Beware of Ibuprofen!
NSAID Toxicity in Dogs & Cats Beware of Ibuprofen! One of the most common drug toxicities in companion animal medicine is accidental ingestion of over-the-counter non-steroid anti-inflammatory (NSAID)
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rycarfa 100 mg tablets for dogs (BE, DE, ES, FR, IE, IT, NL, PT, UK) Rycarfa vet 100 mg tablets for dogs (DK, FI) Carprox
More informationNSAIDs: the Past, Present, and Future
NSAIDs: the Past, Present, and Future Resident Seminar - November 2017 Lisanne Gallant, DVM Large Animal Medicine Resident Outline Physiology Review Use in Large Animals Adverse Effects Cases The Future
More informationNSAIDs Are You Following the Rules?
NSAIDs Are You Following the Rules? As equestrians, we expect a lot from our performance horses. Sometimes pain and inflammation of their joints can happen right before a show or competition. Before administering
More informationMetacam. The Only NSAID Approved for Cats in the US. John G. Pantalo, VMD Professional Services Veterinarian. Think easy. Think cat. Think METACAM.
Metacam The Only NSAID Approved for Cats in the US John G. Pantalo, VMD Professional Services Veterinarian Think easy. Think cat. Think METACAM. Today s Agenda New pain management guidelines for cats Only
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Carprodyl Quadri 120 mg chewable tablets for dogs Carprodyl vet. 120 mg chewable tablets for dogs (FI, SE, DK) 2. QUALITATIVE
More informationIrish Greyhound Board. Scientific Advisory Committee on Doping and Medication Control. Opinion on Carprofen
Irish Greyhound Board Scientific Advisory Committee on Doping and Medication Control Opinion on Carprofen The Committee has been examining the advice it would give the Board on the threshold for carprofen
More informationIs Robenacoxib Superior to Meloxicam in Improving Patient Comfort in Dog Diagnosed With a Degenerative Joint Process?
Is Robenacoxib Superior to Meloxicam in Improving Patient Comfort in Dog Diagnosed With a Degenerative Joint Process? A Knowledge Summary by Adam Swallow BVSc MRCVS 1* 1 University of Bristol * Corresponding
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Animeloxan 1.5 mg/ml oral suspension for dogs. Active substance: Meloxicam 1.5 mg (equivalent to 0.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Animeloxan 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of suspension contains:
More informationThe Journal of Veterinary Medical Science
Advance Publication The Journal of Veterinary Medical Science Accepted Date: 17 Jul 2018 J-STAGE Advance Published Date: 3 Aug 2018 SURGERY FULL PAPER Influence of sevoflurane anesthesia with mechanical
More informationNon-steroidal anti-inflammatory drugs in dogs and cats what s new?
continuing education Nonsteroidal antiinflammatory drugs in dogs and cats what s new? Isabelle Iff Dr.med.vet. DipECVAA CertVetAc (IVAS) Veterinary Anaesthesia Services Zürcherstrasse 39 CH 8400 Winterthur
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 5 mg/ml solution for injection for cattle, pigs, dogs and cats. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 20 mg/ml solution for injection for cattle, pigs and horses. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationDifferential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation
J. vet. Pharmacol. Therap. doi: 10.1111/jvp.12107 Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation L. PELLIGAND*
More informationWhat Veterinarians Should Tell Clients About Pain Control and Their Pets
What Veterinarians Should Tell Clients About Pain Control and Their Pets by Michele Sharkey, DVM, MS, Office of New Animal Drug Evaluation; Margarita Brown, DVM MS, Office of Surveillance and Compliance;
More informationSUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationEPAR type II variation for Metacam
23 June 2011 EMA/674662/2011 International Non-proprietary Name: Meloxicam Procedure No. EMEA/V/C/033/II/084 EU/2/97/004/026, 33-34 Scope: Type II Addition of indication for cats Page 1/6 Table of contents
More informationFaculty of Veterinary Science, Szent Istvan University Department of Pharmacology and Toxicology. Nora Line
Faculty of Veterinary Science, Szent Istvan University Department of Pharmacology and Toxicology Meloxicam usage in cats, and its potential adverse effects on the renal function Nora Line Tutor: György
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Onsior 6 mg tablets for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance:
More informationPain management: making the most of the latest options
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Pain management: making the most of the latest options Author : James Westgate Categories : Business, Business planning Date
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AT, BE, BG, CY, CZ, DE, EE, EL, ES, FR, HR, HU, IE, IT, LT, LU, NL, PT, RO, SK, UK: Kelaprofen 100 mg/ml, solution for injection
More information[09/2018] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
[09/2018] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cronyxin 50 mg/g Oral paste for horses (DE, AT, BE, EE, LV, LT, ES, FR, IE, IT, NL, PL, UK) Cronyxin vet
More informationScientific discussion
21 February 2011 EMA/CVMP/510016/2010 Veterinary Medicines and Product Data Management This module reflects the initial scientific discussion for the approval of Melosus (as published in February 2011).
More informationImplantation of Tissue Chambers in Turkeys: A Pilot Study
CHAPTER 4 4 Implantation of Tissue Chambers in Turkeys: A Pilot Study Aneliya Milanova Haritova 1 and Huben Dobrev Hubenov 2 1 Department of Pharmacology, Veterinary Physiology and Physiological Chemistry,
More informationVeterinary Medicinal Product
Veterinary Medicinal Product Carprodyl Quadri 120 mg chewable tablets for dogs PART I B Pharmaceutical Form Chewable tablet Veterinary Medicinal Product Carprodyl Quadri 120mg chewable tablets for dogs
More informationThe new meloxicam range for cattle, pigs & horses
The new meloxicam range for cattle, pigs & horses Melovem 5 mg/ml Melovem 20 mg/ml Melovem 30 mg/ml The new Melovem range + Many indications for cattle, horses and pigs + Accurate dosing Dopharma has obtained
More informationCaution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
BOEHRINGER INGELHEIM VETMEDICA, INC. USA Product Label http://www.vetdepot.com 2621 NORTH BELT HIGHWAY, ST. JOSEPH, MO, 64506 2002 Telephone: 800 325 9167 Fax: 816 236 2717 Email: www.bi vetmedica.com
More informationchoice The Rilexine Palatable Tablets First generation cephalosporin for skin infections Now registered for ONCE daily administration*
Virbac Dermatology Palatable Tablets The choice First generation cephalosporin for skin infections Now registered for ONCE daily administration* are only available under Veterinary Authorisation. www.virbac.co.nz
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT GALLIPRANT 20 mg tablets for dogs GALLIPRANT 60 mg tablets for dogs GALLIPRANT 100 mg tablets for dogs 2. QUALITATIVE
More informationPrinciples of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1
Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali Lec 1 28 Oct 2018 References Lippincott s IIIustrated Reviews / Pharmacology 6 th Edition Katzung and Trevor s Pharmacology / Examination
More informationSea Turtle Analgesics Selection - NSAIDS. Loggerhead Coquina (postoperative ketorolac)
Sea Turtle Analgesics Selection - NSAIDS Craig A. Harms, D.V.M., Ph.D, Dipl. ACZM North Carolina State University Loggerhead Coquina (postoperative ketorolac) $& Sources of Information!! Anecdote!! Expert
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationABSTRACT. Nonsteroidal anti-inflammatory drugs (NSAIDs), including carprofen, are among the
ABSTRACT MESSENGER, KRISTEN. The Role of Drug and Patient Factors in the Pharmacokinetics of the Nonsteroidal Anti-inflammatory Drug Carprofen in Dogs (Under the direction of Mark Papich). Nonsteroidal
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Loxicom 0.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT EQUIOXX 8.2 mg/g oral paste for horses. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each syringe contains 7.32 g
More informationMeloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration
Inflamm. res. 50, Supplement 1 (2001) S5 S9 1023-3830/01/01S5-05 $ 1.50+0.20/0 Birkhäuser Verlag, Basel, 2001 Inflammation Research Meloxicam: a review of its pharmacokinetics, efficacy and tolerability
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/33
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/33 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Acticam 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of Acticam 1.5
More informationComparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys. Géza Sárközy
Comparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys Géza Sárközy Department of Pharmacology and Toxicology Faculty of Veterinary Science Szent István University
More informationThe Pharmacokinetics of Firocoxib after Multiple Oral Doses to Neonatal Foals. Natasha Hovanessian
The Pharmacokinetics of Firocoxib after Multiple Oral Doses to Neonatal Foals Natasha Hovanessian Thesis submitted to the faculty of the Virginia Polytechnic Institute and State University in partial fulfillment
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Rifen 100 mg/ml solution for injection for horses, cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains:
More informationPain Management in Racing Greyhounds
Pain Management in Racing Greyhounds Pain Pain is a syndrome consisting of multiple organ system responses, and if left untreated will contribute to patient morbidity and mortality. Greyhounds incur a
More informationFREQUENTLY ASKED QUESTIONS Pet Owners
How does the Assisi Loop work? By emitting bursts of microcurrent electricity, the Assisi Loop creates a field which evenly penetrates both soft and hard body tissue around the target area. This electromagnetic
More informationA Current Look at Navicular Syndrome. Patrick First, DVM
A Current Look at Navicular Syndrome Patrick First, DVM Navicular syndrome is a broad term that is used to describe soreness or damage to the navicular bone and its surrounding structures in the equine
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare 20 mg/ml solution for injection for cattle and pigs (UK, IE, FR) Odimar 20 mg/ml solution for injection for cattle
More informationSUMMARY OF PRODUCT CHARACTERISTICS. KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats 2. QUALITATIVE
More informationThe world s first and only pour-on anti-inflammatory for cattle FAST PAIN RELIEF
The world s first and only pour-on anti-inflammatory for cattle FAST PAIN RELIEF NOTHING IS SIMPLER THAN POUR-ON RELIEF FOR PAIN, FEVER AND ACUTE INFLAMMATION easy to dose easy to apply easy on animals
More informationProtein Synthesis Inhibitors
Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products EMEA/MRL/236/97-FINAL June 1997 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS MELOXICAM SUMMARY REPORT (1) 1. Meloxicam (4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide
More informationFinal Report. Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014
Final Report Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014 PUBLISHED BY Meat & Livestock Australia Limited Locked Bag 991 NORTH SYDNEY NSW 2059
More informationMeloxicam, an inhibitor of cyclooxygenase-2, increases the level of serum G-CSF and might
Meloxicam, an inhibitor of cyclooxygenase-2, increases the level of serum G-CSF and might be usable as an auxiliary means in G-CSF therapy Michal Hofer 1, Milan Pospíšil 1, Vladimír Znojil 2, Jiřina Holá
More informationMetacam is an anti-inflammatory medicine used in cattle, pigs, horses, dogs, cats and guinea pigs.
EMA/CVMP/259397/2006 EMEA/V/C/000033 An overview of Metacam and why it is authorised in the EU What is Metacam and what is it used for? Metacam is an anti-inflammatory medicine used in cattle, pigs, horses,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NEFOTEK 100 mg/ml solution for injection for cattle, horses and pigs [AT, CZ, IE, PL, SK, UK, DE, FR, ES, HU, IT, SI] COXOFEN
More informationPrescription Label. Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long):
Prescription Label Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long): Prescribing Veterinarian's Name & Contact Information: Refills: [Content to be provided
More information- Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
MERIAL LTD. USA Product Label http://www.vetdepot.com 3239 SATELLITE BLVD., DULUTH, GA, 30096 Telephone: 888-637-4251 Website: www.merial.com GASTROGARD Merial (omeprazole) Oral Paste for Equine Ulcers
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metacam 5 mg/ml solution for injection for cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More information2008 FELINE HEALTH GRANT AWARDS 10 projects funded for a total of $135,860
2008 FELINE HEALTH GRANT AWARDS 10 projects funded for a total of $135,860 The Winn Feline Foundation receives proposals from veterinary researchers around the world who are interested in improving feline
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metacam 5 mg/ml solution for injection for cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/728/00-FINAL April 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS STREPTOMYCIN AND
More informationIrish Medicines Board
IRISH MEDICINES BOARD ACT 1995 EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (No. 2) REGULATIONS 2007 (S.I. No. 786 of 2007) VPA:10778/003/002 Case No: 7003735 The Irish Medicines Board in exercise of the powers
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrocare 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats (UK, IE, FR) Floxadil 50 mg/ml Solution for Injection
More informationOptimizing Pain Control A Critical Understanding of NSAIDs
Optimizing Pain Control A Critical Understanding of NSAIDs James S. Gaynor, DVM, MS, DACVA, DAAPM Colorado Springs, CO USA 719-266-6400 800-791-2578 www.peakvets.com Principles of Acute & Chronic Pain
More informationAustralian and New Zealand College of Veterinary Scientists. Membership Examination June Veterinary Pharmacology Paper 1
Australian and New Zealand College of Veterinary Scientists Membership Examination June 2012 Veterinary Pharmacology Paper 1 Perusal time: Fifteen (15) minutes Time allowed: Two (2) hours after perusal
More informationIntroduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018
Introduction to Chemotherapeutic Agents Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018 Antimicrobial Agents Substances that kill bacteria without harming the host.
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products EMEA/MRL/571/99-FINAL February 1999 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS MELOXICAM SUMMARY REPORT (2) 1. Meloxicam (4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-
More informationMARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS
MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL 10%, solution for injection for cattle and swine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Marbofloxacin...100.0
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More informationPrinciples of Antimicrobial therapy
Principles of Antimicrobial therapy Laith Mohammed Abbas Al-Huseini M.B.Ch.B., M.Sc, M.Res, Ph.D Department of Pharmacology and Therapeutics Antimicrobial agents are chemical substances that can kill or
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationRVC OPEN ACCESS REPOSITORY COPYRIGHT NOTICE
RVC OPEN ACCESS REPOSITORY COPYRIGHT NOTICE This is the peer reviewed version of an accepted journal article Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and
More informationGuideline on the conduct of efficacy studies for intramammary products for use in cattle
1 2 3 18 October 2013 EMEA/CVMP/EWP/141272/2011 Committee for Medicinal products for Veterinary Use (CVMP) 4 5 6 Guideline on the conduct of efficacy studies for intramammary products for use in cattle
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationCopyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and
Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere
More informationHOW XTC IMPROVED MINOXIDIL PENETRATION - 5 WAYS!
HOW XTC IMPROVED MINOXIDIL PENETRATION - 5 WAYS! What Hinders Minoxidil from Working Well 1. Sebum from sebaceous gland blocks the hair follicle. 2. Minoxidil therefore, cannot penetrate through the sebum
More informationN.C. A and T List of Approved Analgesics 1 of 5
1 of 5 Note to user: This list of commonly used analgesics and sedatives is not all-inclusive. The absence of an agent does not necessarily mean it is unacceptable. For any questions, call the Clinical
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ENROXIL 100 mg/ml solution for injection for cattle and pigs (AT, IE, NL, UK) ENROXAL 100 mg/ml solution for injection for
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT
SUMMARY OF PRODUCT CHARACTERISTICS Revised: December 2013 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Flunixin 50 mg/ml Solution for Injection for Cattle, Horses and Pigs (United Kingdom, Germany, Iceland)
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE
European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/211249/2005-FINAL July 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE DIHYDROSTREPTOMYCIN (Extrapolation to all ruminants)
More informationA Brief Overview of the Coxib Drugs in the Veterinary Field
American Journal of Animal and Veterinary Sciences 8 (2): 89-97, 2013 ISSN: 1557-4555 2013 Kim and Giorgi et al., This open access article is distributed under a Creative Commons Attribution (CC-BY) 3.0
More informationApproved for Orthopedic and Soft-tissue Surgery
Approved for Orthopedic and Soft-tissue Surgery tlr8.5x11_rsg2 3/17/1 11:36 AM Page 4 Designed for Dogs bout NSAIDs Facts about NSAIDs f NSAIDs is to relieve the pain and ssociated with surgery with a
More informationThis article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and
This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution
More informationPHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL MELOXICAM TABLETS IN HEALTHY HORSES KARIE VANDER WERF
PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL MELOXICAM TABLETS IN HEALTHY HORSES by KARIE VANDER WERF B.S., University of Florida, 2000 D.V.M., Ross University School of Veterinary Medicine, 2005 A THESIS
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Selectan 300 mg/ml solution for injection for cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationAuthor - Dr. Josie Traub-Dargatz
Author - Dr. Josie Traub-Dargatz Dr. Josie Traub-Dargatz is a professor of equine medicine at Colorado State University (CSU) College of Veterinary Medicine and Biomedical Sciences. She began her veterinary
More informationMeloxicam withdrawal time veterinarian bovine
Meloxicam withdrawal time veterinarian bovine The Borg System is 100 % Meloxicam withdrawal time veterinarian bovine Meloxicam Pain Relief in Cows and Calves. Meloxicam meat and milk withdrawal the standard
More informationPharmacokinetic/pharmacodynamic modeling for the determination of a cimicoxib dosing regimen in the dog
Jeunesse et al. BMC Veterinary Research 203, 9:250 RESEARCH ARTICLE Open Access Pharmacokinetic/pharmacodynamic modeling for the determination of a cimicoxib dosing regimen in the dog Elisabeth C Jeunesse,4*,
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More information1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Summary of Prodcuct Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrox Max 100 mg/ml Solution for Injection for Cattle and Pigs Enroxal Max 100 mg/ml Solution for Injection for Cattle and
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Amphen 200 mg/g Granules for use in drinking water for pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each g contains: Active
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rheumocam 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains: Active
More informationComparison of Robenacoxib and carprofen in palliative management of cancer pain
Comparison of Robenacoxib and carprofen in palliative management of cancer pain Department of Veterinary Medicine of Companion Animals at University Utrecht Research Project of L.M.A. van der Hoeven Supervisor:
More informationISMP Canada HYDROmorphone Knowledge Assessment Survey
ISMP Canada HYDROmorphone Knowledge Assessment Survey Knowledge Assessment Questions 1. In an equipotent dose, HYDROmorphone is more potent than morphine. True False Unsure 2. HYDROmorphone can be given
More informationFluralaner (mg) for small cats kg for medium-sized cats > kg for large cats > kg 1.
1. NAME OF THE VETERINARY MEDICINAL PRODUCT Bravecto 112.5 mg spot-on solution for small cats (1.2 2.8 kg) Bravecto 250 mg spot-on solution for medium-sized cats (>2.8 6.25 kg) Bravecto 500 mg spot-on
More information